• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Americans Are Losing Patience with Innovation That Doesn't Make Life Better, New Poll from PMI U.S. Finds

    6/30/26 7:02:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email

    Nearly 8 in 10 Americans surveyed say the country is innovating in the wrong areas, while 86% say the most meaningful innovations are not the headline makers but those that solve problems ordinary people face every day.

    STAMFORD, Conn., June 30, 2026 /PRNewswire/ -- Americans are not losing faith in innovation. They are losing patience with innovation that asks for applause before it delivers proof. A new nationwide survey from Philip Morris International's U.S. businesses (PMI U.S.) finds that Americans still believe innovation can help build a better future—but only if it makes life more affordable, safer, healthier, or easier to navigate in the communities where people live.

    PMI U.S. America250

    Innovation has long been a driver of America's economic growth, prosperity, and opportunity. As a company rooted in science and technology, PMI U.S. commissioned The Harris Poll to conduct this research to better understand Americans' expectations of innovation and where they believe it can make the greatest difference in their daily lives. The findings reveal a growing credibility challenge for companies: while 76% of Americans surveyed say innovation will play a major role in building the nation's future, 81% say corporate rhetoric about innovation often feels disconnected from real-world problems, and nearly 8 in 10 (79%) believe the country is innovating in the wrong areas. The message is clear: Americans still believe in the power of innovation, but they want it focused on solving tangible problems and delivering meaningful benefits in their communities.

    "Americans are not rejecting innovation. They are rejecting innovation that feels detached from their lives," said Stacey Kennedy, CEO, PMI U.S. "Companies need to show that what they are building solves real problems, serves real people, and strengthens real communities. That is the standard PMI U.S. is working to meet."

    The findings suggest that innovation has a permission problem. More than three-quarters of respondents (77%) agree that too much innovation today feels designed for hype rather than impact. Nearly 9 in 10 (86%) say the most meaningful innovation solves real-world problems people face every day, and 89% say they are more likely to believe a company's innovation claims when they can see tangible benefits at the local level. In short: Novelty is not enough. Americans want usefulness they can see.

    The survey also shows where trust still lives: close to home. Americans are more confident in the direction their local communities are taking (58%) than in where the country as a whole is headed (43%). When respondents were asked what gives them confidence in the country's future, "everyday people in local communities" (65%), "local businesses and entrepreneurs" (61%), and "local nonprofits and community organizations" (59%) outranked large corporations (44%) and the federal government (41%). These results seem to suggest that the more distance from one's community, the less confidence Americans have in that institution.

    The higher confidence in locally grown solutions comes with a warning for companies: Do not arrive as the hero. Nine in 10 Americans (90%) say companies should act as partners rather than presume they have all the answers. Communities are looking for long-term commitment from their partners (91%), connection with other communities solving similar problems (91%), investment (89%), access to tools and expertise (88%), and platforms that amplify ideas already creating progress (88%). The takeaway is that they do not need more corporate theater. They need help making what works go further.

    The mismatch between expectations and reality is especially stark in where Americans believe companies are placing their bets. Respondents see companies pouring attention and resources into AI and machine learning, apps and software, and space or moonshot projects. They want more focus on the problems that show up in the family budget: reducing the cost of everyday life, making healthcare more accessible, creating good-paying local jobs, making housing more affordable, improving schools, making neighborhoods safer, supporting small businesses, and helping communities become more resilient.

    The research also cuts through the usual story that Americans cannot agree on anything. They can. Healthcare affordability, housing affordability, and good-paying jobs that do not require a four-year degree rank as the top priorities Americans want innovation to address, followed by schools, trust in institutions, infrastructure, small businesses, resilience, and more equitable access to innovation. The divide is not over what hurts. It is over whether institutions are serious about fixing it.

    Across the 10 cities included in the survey—Atlanta, Chicago, Houston, Jacksonville, Los Angeles, Nashville, New York, Phoenix, Pittsburgh, and Stamford—the findings point to another uncomfortable truth: There is no single national innovation story that works everywhere. Residents consistently identified practical progress, local problem-solving, and community-led opportunity as signs of meaningful innovation. The strongest story is not a slogan pushed from the center. It is proof, adapted market by market, that people can recognize as real.

    The city-level findings show how sharply the innovation story changes by market. Stamford is the confident market, with 71% saying innovation in America is thriving and moving in the right direction, compared with 62% nationally. Nashville is a proof-demanding market, with 85% saying America is innovating in the wrong areas and solving the wrong problems for the wrong people. Chicago is the community-potential market, with 92% saying the next big American idea could come from any community, not just a traditional innovation hub. Phoenix puts affordability at the center of the innovation test, while Los Angeles shows that even markets associated with creativity and technology still need clearer local proof, coordination, and amplification.

    Market pattern

    Cities

    What it shows

    Key data

    Where the Innovation Story Splits

    Chicago, Nashville, Stamford

    These markets show the sharpest differences in what residents need from innovation: proof that it is aimed at the right problems, evidence that confidence is warranted, or belief that the next big idea can come from any community.

    Chicago: 92% say the next big American idea could come from any community.

    Nashville: 85% say America is innovating in the wrong areas.

    Stamford: 71% say innovation in America is thriving and moving in the right direction.

    Where Usefulness Beats Hype

    Jacksonville, New York, Pittsburgh

    These markets are not asking for a bigger innovation story. They are asking for a more useful one tied to healthcare, jobs, cost of living, housing, partnership, and visible community benefit.

    Jacksonville: 88% say practical, community-led innovation earns more trust than chasing the next big thing.

    New York: Community confidence outpaces confidence in the nation, 52% to 38%.

    Pittsburgh: 87% are more likely to believe in company innovation when they can see how it benefits real communities.

    Where Generic Innovation Falls Short

    Atlanta,

    Houston,

    Los Angeles,

    Phoenix

    These markets show why one-size-fits-all innovation messaging underperforms. Each applies a different local test: next-generation opportunity, affordability, usefulness at scale, or clearer proof and amplification.

    Atlanta: 88% say America's next chapter depends on ideas from communities across the country.

    Houston: 86% say meaningful innovation solves everyday problems.

    Los Angeles: 91% say communities need platforms that surface what is already working.

    Phoenix: 88% say communities need funding and investment to turn good ideas into real progress.

    For PMI U.S., the findings reinforce that innovation should be measured by real-world impact. By advancing modern nicotine alternatives to help legal-age adults move away from combustible cigarettes, creating meaningful partnerships within communities, and investing in American manufacturing, operations, and jobs, PMI U.S. is promoting progress nationwide as it builds its future in the United States.

    Since 2022, PMI U.S. has invested more than $1 billion in U.S. manufacturing, operational capabilities, and people costs. PMI U.S. employs more than 3,300 people across the country, and operates manufacturing facilities in Colorado, Kentucky, and North Carolina. Those investments reflect that the business is holding the development, manufacturing, and commercialization of its modern nicotine products to the same proof standard Americans are applying to innovation more broadly: prioritizing better choices, economic contribution, responsible practices, and tangible community impact.

    Read more about the survey and register for the forthcoming whitepaper here: https://www.uspmi.com/en/america250/

    Survey Methodology

    The Harris Poll was conducted online on behalf of PMI U.S. between May 19 and June 2, 2026. The survey sample consisted of 2,000 U.S. adults aged 21 and older. National results were weighted by age, gender, region, race/ethnicity, household income, education, marital status, household size, employment status, and political party affiliation. The national sample has a Bayesian credible interval of ±3.1 percentage points at a 95% confidence level. The research also included market-level samples of approximately 200 adults in each of 10 cities: Atlanta, Chicago, Houston, Jacksonville, Los Angeles, Nashville, New York, Phoenix, Pittsburgh, and Stamford.

    About PMI U.S.

    Philip Morris International Inc.'s U.S. businesses (PMI U.S.) are invested in America's future and advancing a smoke-free nation. The businesses are committed to providing the approximately 25 million legal-age consumers who smoke cigarettes with better, smoke-free alternatives and to ensuring the products are marketed responsibly. From PMI's global headquarters in Stamford, Connecticut, and other locations nationwide, PMI U.S. contributes leadership, jobs, investment, and innovation in the U.S. PMI U.S. employ more than 3,300 people across America and operate product manufacturing facilities, including in Aurora, Colorado; Owensboro, Kentucky; and Wilson, North Carolina. For more information, please visit www.uspmi.com.

    References to "PMI" mean the Philip Morris International family of companies. "PMI U.S.," "we," "our," and "us" refer to one or more PMI U.S. businesses.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/americans-are-losing-patience-with-innovation-that-doesnt-make-life-better-new-poll-from-pmi-us-finds-302814435.html

    SOURCE PMI US Corporate Services, Inc.

    Get the next $PM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    1/20/2026$180.00Buy → Hold
    Jefferies
    7/9/2025$220.00Buy
    Jefferies
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    More analyst ratings

    $PM
    SEC Filings

    View All

    Philip Morris International Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    7/9/26 4:05:53 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Inc filed SEC Form 8-K: Other Events

    8-K - Philip Morris International Inc. (0001413329) (Filer)

    6/29/26 4:05:25 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 11-K filed by Philip Morris International Inc

    11-K - Philip Morris International Inc. (0001413329) (Filer)

    6/29/26 12:57:08 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Combes Michel was granted 1,119 shares, increasing direct ownership by 11% to 11,643 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:23 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Geissler Werner was granted 1,119 shares, increasing direct ownership by 1% to 98,356 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:18 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Morparia Kalpana was granted 1,119 shares, increasing direct ownership by 4% to 28,236 units (SEC Form 4)

    4 - Philip Morris International Inc. (0001413329) (Issuer)

    5/8/26 2:01:11 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philip Morris International to Host Webcast of 2026 Second-Quarter and First Six-Months Results

    Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast on Wednesday, July 22, 2026, at 9:00 a.m. ET, to discuss its 2026 second-quarter and first six-months financial results, which will be issued at approximately 7:00 a.m. ET the same day. The webcast can be accessed here. The webcast will be hosted by Emmanuel Babeau, Group Chief Financial Officer, and Massimo Andolina, incoming Group CFO, and will include discussion of PMI’s financial results and a Q&A session with the investment community. The webcast will be in a listen-only mode. The webcast may also be accessed on mobile devices by downloading PMI’s Investor Relations App at www.pmi.com

    7/15/26 10:02:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    PMI U.S. Unveils the ZYN America250 Art Series, Bringing Modern Culture to Limited-Edition Cases

    Featuring original designs from acclaimed artists, the nationwide initiative celebrates America's 250th anniversary through collectible metal ZYN cases STAMFORD, Conn., July 3, 2026 /PRNewswire/ -- Philip Morris International's U.S. businesses (PMI U.S.) today announced the launch of the ZYN America250 Art Series, a cultural initiative from America's No. 1 nicotine pouch brand, celebrating the nation's 250th anniversary through the lens of contemporary American art and creative expression. The ZYN America250 Art Series brings together a curated group of American and U.S.-based a

    7/3/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products

    FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE:PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." "FDA’s decision is an important moment for the more than 45 m

    6/30/26 12:19:00 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Philip Morris International downgraded by Jefferies with a new price target

    Jefferies downgraded Philip Morris International from Buy to Hold and set a new price target of $180.00

    1/20/26 9:10:49 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on Philip Morris International with a new price target

    Jefferies resumed coverage of Philip Morris International with a rating of Buy and set a new price target of $220.00

    7/9/25 8:31:10 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Needham initiated coverage on Philip Morris International with a new price target

    Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

    5/22/25 8:27:06 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    View All

    PMI U.S. Expands Its Talent Pipeline and Welcomes New Class of Interns Across the Enterprise

    Intern class doubles to 25, signaling expanded investment in early-career talent STAMFORD, Conn., May 18, 2026 /PRNewswire/ -- Today, Philip Morris International's U.S. business (PMI U.S.) announced expanded internship and early‑career programs across the organization, underscoring its commitment to developing the next generation of talent to grow the business and innovate its industry. The programs are designed to provide meaningful experience, exposure, and opportunity for students just beginning their careers and early-career professionals ready to accelerate their impact. This summer, PMI U.S. will welcome its second intern

    5/18/26 8:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI

    The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE:PM) today released a new white paper, "Human Cognition: The Next Frontier?", inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the "superskill" of the future, driving progress in an era of human-machine collaboration. As AI automates routine ta

    1/20/26 5:03:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

    Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

    9/17/24 9:11:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Financials

    Live finance-specific insights

    View All

    Philip Morris International Declares Regular Quarterly Dividend of $1.47 Per Share

    Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.47 per common share, payable on July 20, 2026, to shareholders of record as of June 25, 2026. The ex-dividend date is June 25, 2026. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: A Global Smoke-Free Champion Philip Morris International is a leading international consumer goods company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily cons

    6/11/26 6:00:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Participates in 2026 dbAccess Global Consumer Conference; Updates 2026 Full-Year Diluted EPS Forecast for Currency and Non-Cash Impairment Only

    Regulatory News: Philip Morris International Inc.'s (PMI) (NYSE:PM) Group CEO PMI, Jacek Olczak, will address investors today at the 2026 dbAccess Global Consumer Conference in Paris at 11:15 a.m. CET (5:15 a.m. ET), including discussion of the following topics: PMI's continued expectation of a strong full-year performance, notably driven by the broad-based momentum of our international multicategory smoke-free business, led by IQOS. Recent heat-not-burn category developments broadly in-line with our expectations, most notably in Japan following the April 1, 2026 excise tax increase, with April offtake impacted by consumer pantry de-loading and IQOS maintaining a strong category sh

    6/2/26 1:30:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    Philip Morris International Reports 2026 First-Quarter Results and Updates 2026 Full-Year Adjusted Diluted EPS Forecast for Currency Only;

    Reported Diluted EPS declined by 9.3% to $1.56; Adjusted Diluted EPS grew by 16.0% to $1.96; and by 5.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2026 first quarter results.1 "Our performance exceeded our expectations in the first quarter, with an outstanding delivery from IQOS driving very good growth for the group against a strong prior-year comparison," said Jacek Olczak, Group CEO PMI. "Building on excellent broad-based momentum in the international smoke-free business and 16% adjusted diluted EPS growth in Q1, we are well positioned to continue delivering best-in-class performance in 2026." ____________________

    4/22/26 6:59:00 AM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:21:26 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    2/9/24 6:05:54 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

    SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

    1/29/24 3:26:29 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care